Hydrochloric Acid

Hydrochloric Acid

SCHEMBL202467

C[C@H](N)CN.Cl.Cl

nearest known ligand 0.00

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO

The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 96 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-RE49556-E1 Compounds and compositions as protein kinase inhibitors ARRAY BIOPHARMA INC. (US) 2023-06-20 US disclosed
CN-113980032-B Fused tetracyclic derivative, preparation method thereof and application thereof in medicines 江苏恒瑞医药股份有限公司 2023-06-16 CN disclosed
US-20230116233-A1 Compounds And Compositions As Protein Kinase Inhibitors ARRAY BIOPHARMA INC (US) 2023-04-13 US disclosed
CN-113336661-B Preparation method of methyl tetraacetate compound 南京正大天晴制药有限公司 2022-08-05 CN disclosed
CN-113336661-A Preparation method of methyl tetraacetate compound 南京正大天晴制药有限公司 2021-09-03 CN disclosed
US-10954251-B2 Thienopyrimidine inhibitors of atypical protein kinase C CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2021-03-23 US disclosed
CN-107207407-B Compositions and methods for treating diseases and disorders 高等教育联邦系统-匹兹堡大学 2020-12-01 CN disclosed
US-20200323852-A1 Compounds And Compositions As Protein Kinase Inhibitors IRM LLC (BM) 2020-10-15 US disclosed
US-10576080-B2 Compounds and compositions as protein kinase inhibitors ARRAY BIOPHARMA INC. (US) 2020-03-03 US disclosed
US-10568884-B2 Compounds and compositions as protein kinase inhibitors ARRAY BIOPHARMA INC. (US) 2020-02-25 US disclosed
US-6211107-B1 Process for expoxidizing prochiral olefins and a catalyst therefor and intermediates for making the catalyst SMITHKLINE BEECHAM P.L.C. (GB) 2001-04-03 US disclosed
WO-2001016136-A2 TRICYCLIC INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASES AGOURON PHARMACEUTICALS, INC. (US) 2001-03-08 WO disclosed
EP-0611369-B1 PROCESS FOR PREPARING (S) (+)-4,4'-(1-METHYL-1,2-ETHANEDIYL)-BIS(2,6-PIPERAZINEDIONE) EUROCETUS BV (NL) 1999-07-28 EP disclosed
US-5916975-A Process for epoxidising prochiral olefins and a catalyst therefor and intermediates for making the catalyst SMITHKLINE BEECHAM P.L.C. (GB) 1999-06-29 US disclosed
US-5618936-A CYCLIZATION OF 1,2-DIAMINOPROPANE TETRAACETIC ACID OR SODIUM SALT SICOR SPA (IT) 1997-04-08 US disclosed
EP-0330381-B1 Process for preparing bis (3,5-dioxopiperazinyl) alkanes or alkenes ERBAMONT INC (US) 1995-05-24 EP disclosed
EP-0611369-A1 PROCESS FOR PREPARING (S) (+)-4,4'-(1-METHYL-1,2-ETHANEDIYL)-BIS(2,6-PIPERAZINEDIONE) EUROCETUS BV (NL) 1994-08-24 EP disclosed
WO-1993008172-A1 PROCESS FOR PREPARING (S) (+)-4,4'-(1-METHYL-1,2-ETHANEDIYL)-BIS(2,6-PIPERAZINEDIONE) EUROCETUS BV (NL) 1993-04-29 WO disclosed
US-4963679-A Process for preparing bis (3,5-dioxopiperazinyl) alkanes or alkenes ERBAMONT, INC. (US) 1990-10-16 US disclosed
EP-0330381-A1 Process for preparing bis (3,5-dioxopiperazinyl) alkanes or alkenes ERBAMONT, INC. (US) 1989-08-30 EP disclosed